Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 152.50
Bid: 150.00
Ask: 155.00
Change: -5.00 (-3.17%)
Spread: 5.00 (3.333%)
Open: 157.50
High: 157.50
Low: 152.50
Prev. Close: 157.50
ITX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Marketing approval of nicotine gum in Europe

20 Nov 2013 07:00

RNS Number : 4427T
Revolymer PLC
20 November 2013
 



20th November, 2013

Revolymer plc

Revolymer files for marketing approval of its nicotine gum in Europe

Revolymer plc ("Revolymer" or the "Company"), the British polymer technology company, is pleased to announce that, on the 19th November 2013, its wholly-owned UK operating subsidiary Revolymer (U.K.) Limited filed for marketing authorisation in Europe of its proprietary nicotine gum products by submitting an application under Directive 2001/83/EC to the Medicines and Healthcare products Regulatory Agency (MHRA).

If approved, such authorisation will permit the marketing of Revolymer's 2mg and 4mg strength nicotine gum in the UK, Ireland, Poland and Spain. These countries are expected to be the first in Europe where Revolymer's nicotine gum products will be sold. Revolymer has already established a supply and distribution agreement for its nicotine gum in Poland, and aims to conclude commercialisation deals in the UK, Ireland and Spain in due course. The Company also plans to apply for marketing authorisations for additional countries in Europe as it establishes appropriate commercial pathways.

Roger Pettman, Chief Executive of Revolymer said: "I am pleased that our strategy to commercialise our nicotine gum products in Europe is progressing, as demonstrated by the achievement of this latest milestone. We believe that not only is our product bioequivalent to the existing reference product in Europe, but that it has additional benefits that consumers will value, namely a more confectionery-like chew."

The establishment of further nicotine gum commercialisation deals in Europe and the filing for regulatory approval of its nicotine gum in the US are expected to be the subject of future announcements by the Company.

 

Ends

 

For further information please contact:

 

Revolymer plc

+44 (0) 1244 283 500

Roger Pettman

Rob Cridland

 

 

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Callum Stewart / Adam James (Corporate Finance)

Adam Pollock / Charles Leigh-Pemberton (Corporate Broking)

 

Citigate Dewe Rogerson

+44 (0)20 7282 2945

David Dible / Ginny Pulbrook/Malcolm Robertson

 

 

 

About Revolymer

Revolymer is a technology company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the fast moving consumer goods (FMCG) and other industrial markets. Revolymer aims to generate significant and growing high quality revenue streams by licensing its unique technologies to manufacturers and marketers within these markets. Potential applications for the business's technologies are in the household products, personal care and coatings & adhesives product areas (together "Consumer Specialties") and in medicated chewing gum (including nicotine gum) and confectionery chewing gum (together "Gum").

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKMMMMKLDGFZM
Date   Source Headline
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company
12th Sep 20237:00 amRNSHalf year results
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
22nd Aug 20237:00 amRNSShare Consolidation & Total Voting Rights
15th Aug 20237:00 amRNSShare Consolidation
12th Jul 20237:00 amRNSTrading Update
28th Jun 202312:29 pmRNSAGM Statement
5th Jun 20237:00 amRNSFinal Results
24th May 20237:00 amRNSNotice of Final Results, Briefings, and AGM
25th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
2nd Mar 20233:25 pmRNSTR-1
1st Mar 20237:00 amRNSAward from Frost & Sullivan
28th Feb 20236:03 pmRNSTR-1
28th Feb 20235:04 pmRNSTR-1
28th Feb 20233:09 pmRNSTR-1
23rd Feb 20237:00 amRNSTR-1
22nd Feb 202312:28 pmRNSResults of Open Offer, GM and Total Voting Rights
15th Feb 20237:00 amRNSInvestor Presentation following GM on 22 Feb 2023
3rd Feb 20237:00 amRNSPlacing, Subscription and Open Offer; Notice of GM
5th Jan 20237:00 amRNSBoard Change
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSItaconix and Brenntag Promote Sustainable Cleaning
14th Sep 20227:00 amRNSHalf year results
13th Sep 202211:05 amRNSSecond Price Monitoring Extn
13th Sep 202211:00 amRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSItaconix and Croda Renew Supply Agreement
20th Jul 20227:00 amRNSBoard Change
13th Jul 20227:00 amRNSTrading Update
5th Jul 20227:00 amRNSDirectorate Change
1st Jul 20222:37 pmRNSResult of AGM
1st Jul 20229:00 amRNSPrice Monitoring Extension
1st Jul 20227:00 amRNSAGM Statement and Notice of Capital Markets Event
29th Jun 20227:00 amRNSNotice of Capital Markets Webinar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.